@article {Wallach19000463, author = {Joshua D Wallach and Kun Wang and Audrey D Zhang and Deanna Cheng and Holly K Grossetta Nardini and Haiqun Lin and Michael B Bracken and Mayur Desai and Harlan M Krumholz and Joseph S Ross}, title = {Updating Insights into Rosiglitazone and Cardiovascular Risk through Shared Data: Individual Patient- and Summary-Level Meta-Analyses}, elocation-id = {19000463}, year = {2019}, doi = {10.1101/19000463}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Objective To conduct a systematic review and meta-analysis of the effects of rosiglitazone therapy on cardiovascular risk and mortality using multiple data sources and varying analytical approaches.Design Systematic review and meta-analysis of randomized controlled trials.Data sources GlaxoSmithKline{\textquoteright}s (GSK) Clinical Study Data Request (CSDR) and Study Register platforms, MEDLINE, PubMed, Embase, Web of Science, Cochrane Central Registry of Controlled Trials, Scopus, and ClinicalTrials.gov from inception to January 2019.Study selection criteria Randomized, controlled, phase II-IV clinical trials comparing rosiglitazone with any control for at least 24 weeks in adults.Data extraction and synthesis For analyses of trials for which individual patient-level data (IPD) were available, we examined a composite of the following events as our primary outcome: acute myocardial infarction, heart failure, cardiovascular-related deaths, and non-cardiovascular-related deaths. As secondary analyses, these four events were examined independently. When also including trials for which IPD were not available, we examined myocardial infarction and cardiovascular-related deaths, ascertained from summary-level data. Multiple meta-analyses were conducted, accounting for trials with zero events in one or all arms with two different continuity corrections (i.e., 0.5 constant and treatment arm comparator continuity correction), to calculate odds ratios and risk ratios with 95\% confidence intervals.Results There were 33 eligible trials for which IPD were available (21156 participants) through GSK{\textquoteright}s CSDR. We also identified 103 additional trials for which IPD were not available from which we ascertained myocardial infarctions (23683 patients) and 103 trials for cardiovascular-related deaths (22772 patients). Among trials for which IPD were available, we identified a greater number of myocardial infarctions and fewer cardiovascular-related deaths reported in the IPD as compared to the summary-level data. When limited to trials for which IPD were available and accounting for trials with zero-events in only one arm using a constant continuity correction of 0.5, patients treated with rosiglitazone had a 39\% increased risk of a composite event compared with controls (Mantel-Haenszel odds ratio 1.39, 95\% CI 1.15 to 1.68). When examined separately, the odds ratios for myocardial infarction, heart failure, cardiovascular-related death, and non-cardiovascular-related death were 1.25 (0.99 to 1.60), 1.60 (1.20 to 2.14), 1.18 (0.64 to 2.17), and 1.13 (0.58 to 2.20), respectively. When all trials for which IPD were and were not available were combined for myocardial infarction and cardiovascular-related deaths, the odds ratios were attenuated (1.13 (0.92 to 1.38) and 1.10 (0.73 to 1.65), respectively). Effect estimates and 95\% confidence intervals were broadly consistent when analyses were repeated including trials with zero events across all arms using constant continuity corrections of 0.5 or treatment arm continuity corrections.Conclusions Results of this comprehensive meta-analysis aggregating a multitude of trials and analyzed using a variety of statistical techniques suggest that rosiglitazone is consistently associated with an increased cardiovascular risk, likely driven by heart failure events, whose interpretation is complicated by varying magnitudes of myocardial infarction risk that were attenuated through aggregation of summary-level data in addition to IPD.Systematic review registration https://osf.io/4yvp2/What is already known on this topic- Since 2007, there have been multiple meta-analyses, using various analytic approaches, that have reported conflicting findings related to rosiglitazone{\textquoteright}s cardiovascular risk.- Previous meta-analyses have relied primarily on summary-level data, and did not have access to individual patient-level data (IPD) from clinical trials.- Currently, there is little consensus on which method should be used to account for sparse adverse event data in meta-analyses.What this study adds- Among trials for which IPD were available, rosiglitazone use was consistently associated with an increased cardiovascular risk, likely driven by heart failure events.- Interpretation of rosiglitazone{\textquoteright}s cardiovascular risk is complicated by varying magnitudes of myocardial infarction risk that were attenuated through aggregation of summary-level data in addition to IPD.- Among trials for which IPD were available, we identified a greater number of myocardial infarctions and fewer cardiovascular deaths reported in the IPD as compared to the summary-level data, which suggests that IPD may be necessary to accurately classify all adverse events when performing meta-analyses focused on safety.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at?www.icmje.org/coi_disclosure.pdf?and declare:?In the past 36 months, JDW received research support through the Meta Research Innovation Center at Stanford (METRICS) from the Laura and John Arnold Foundation. ADZ received research support through the Yale-Mayo Clinic CERSI (U01FD005938). MB is currently, or within the last 4 years has been, a consultant to Eli Lilly, Forest Laboratories, Glaxo Inc., and Lundbeck Inc., all on matters unrelated to the content of this manuscript. HMK received research support through Yale from Johnson and Johnson to develop methods of clinical trial data sharing, from Medtronic, Inc. and the Food and Drug Administration (FDA) to develop methods for postmarket surveillance of medical devices (U01FD004585), from the Centers of Medicare and Medicaid Services (CMS) to develop and maintain performance measures that are used for public reporting, received payment from the Arnold \& Porter Law Firm for work related to the Sanofi clopidogrel litigation and from the Ben C. Martin Law Firm for work related to the Cook IVC filter litigation, chairs a Cardiac Scientific Advisory Board for UnitedHealth, is a participant/participant representative of the IBM Watson Health Life Sciences Board, is a member of the Advisory Board for Element Science and the Physician Advisory Board for Aetna, and is the founder of Hugo, a personal health information platform. JSR received research support through Yale from Johnson and Johnson to develop methods of clinical trial data sharing, from Medtronic, Inc. and the Food and Drug Administration (FDA) to develop methods for postmarket surveillance of medical devices (U01FD004585), from the Centers of Medicare and Medicaid Services (CMS) to develop and maintain performance measures that are used for public reporting, from the FDA to establish a Center for Excellence in Regulatory Science and Innovation (CERSI) at Yale University and the Mayo Clinic (U01FD005938), from the Blue Cross Blue Shield Association to better understand medical technology evaluation, and from the Agency for Healthcare Research and Quality (R01HS022882).Clinical TrialNot applicable. This is a meta-analysisFunding StatementThis project was conducted as part of the Collaboration for Research Integrity and Transparency (CRIT) at Yale, funded by the Laura and John Arnold Foundation, which supports JDW, ADZ, and JSR. These funders played no role in the design of the study, analysis or interpretation of findings, or drafting the manuscript and did not review or approval the manuscript prior to submission. The authors assume full responsibility for the accuracy and completeness of the ideas presented.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.NAAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.NAI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesThe dataset will be made available via a publicly accessible repository on journal publication: https://osf.io/4yvp2/.https://osf.io/4yvp2/.}, URL = {https://www.medrxiv.org/content/early/2019/06/25/19000463}, eprint = {https://www.medrxiv.org/content/early/2019/06/25/19000463.full.pdf}, journal = {medRxiv} }